Evidence map›Paper›PMID 42237624›Full record

ArticleJournal of stroke2026

Outcomes of Early Versus Later Anticoagulation in Asian Atrial Fibrillation-Related Stroke: ELAN Subgroup Analysis.

Takeshi Yoshimoto, Masafumi Ihara, P N Sylaja, Jean-Benoît Rossel, Shigeru Fujimoto, Yasuyuki Iguchi, Rajsrinivas Parthasarthy, Vijaya Pamidimukkala, Yusuke Yakushiji, Thomas Iype and 15 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03148457 (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03148457 nacompletednot on this map

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

TypeinterventionalSponsorInsel Gruppe AG, University Hospital BernRan2017 to 2023Enrolled2,013ConditionsIschaemic StrokeArmsEarly treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®), Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Takeshi YoshimotoDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
Masafumi IharaDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
P N SylajaDepartment of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Medical College PO, Thiruvananthapuram, India.
Jean-Benoît RosselDepartment of Clinical Research, University of Bern, Bern, Switzerland.
Shigeru FujimotoDivision of Neurology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Yasuyuki IguchiDepartment of Neurology, Jikei University School of Medicine, Tokyo, Japan.
Rajsrinivas ParthasarthyDepartment of Neurointerventional Surgery, Paras Health, Lucknow, India.
Vijaya PamidimukkalaLalitha super Specialities Hospital, Guntur, India.
Yusuke YakushijiDepartment of Neurology, Kansai Medical University, Hirakata, Japan.
Thomas IypeGovernment Medical College Thiruvananthapuram, Thiruvananthapuram, India.
Makoto NakajimaDepartment of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Dheeraj KhuranaDepartment of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Vivek NambiarDivision of Stroke, Department of Neurology, Amrita Institute of Medical Sciences, Kochi, India.
Hisanao AkiyamaDepartment of Neurology, St. Marianna University School of Medicine, Kawasaki, Japan.
Kazunori ToyodaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Angelika AlonsoDepartment of Neurology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Sven PoliDepartment of Neurology & Stroke, Tübingen University, Tübingen, Germany.
Caterina KulykDepartment of Neurology, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
Nicoletta G CaraccioloStroke Unit, Policlinico Umberto I, Rome, Italy.
Dimitri HemelsoetDepartment of Neurology, Ghent University Hospital, Gent, Belgium.
Ana Paiva NunesStroke Unit, Lisbon Central University Hospital, Lisbon, Portugal.
Jeyaraj Durai PandianDepartment of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Medical College PO, Thiruvananthapuram, India.
Jesse DawsonSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
Urs FischerDepartment of Neurology, University Hospital Bern, University of Bern, Bern, Switzerland. urs.fischer@insel.ch.
Masatoshi KogaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Funding

National Cerebral and Cardiovascular Center 20-4-5Stroke Association in the United Kingdom 2017/02Swiss Academy of Medical Sciences/Bangerter-Rhyner Foundation YTCR_13/18Swiss Heart FoundationSwiss National Science Foundation 32003B_169975Swiss National Science Foundation 32003B_197009
6 · The paper itself

Abstract

Background and Purpose: We aimed to evaluate whether early versus late initiation of direct oral anticoagulant (DOAC) after acute ischemic stroke (AIS) yields different safety and efficacy outcomes in Asian versus non-Asian patients. Methods: We analyzed Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN) trial data from 2,013 AIS patients with atrial fibrillation (AF) randomized to early (≤48 hours for minor/moderate stroke, 6-7 days for major stroke) or late DOAC initiation (3-4 days for minor ischemic stroke, 6-7 days for moderate ischemic stroke, 12-14 days for major ischemic stroke). Patients were categorized by region as Asian (Japan and India) or non-Asian. The primary outcome was a composite of major extracranial bleeding, symptomatic intracranial hemorrhage (SICH), recurrent ischemic stroke, systemic embolism (SE), or vascular death at 30 days (trial registration: ClinicalTrials.gov number, NCT03148457). Results: Among 1,975 patients, 245 were Asian (192 from Japan and 53 from India) and 1,730 were non-Asian. The primary outcome occurred in 6.5% of Asian patients (4.8% early vs. 8.3% late) and 3.1% of non-Asian patients (2.7% vs. 3.6%) (P<0.01). Higher rates of recurrent ischemic stroke (4.1% [2.4% vs. 5.8%] vs. 1.7% [1.3% vs. 2.1%], P=0.02) and SE (2.0% [0.8% vs. 3.3%] vs. 0.5% [0.4% vs. 0.6%], P=0.02) accounted for this difference. No significant differences were observed in major extracranial bleeding, SICH, recurrent ischemic stroke, SE, or vascular death. No significant interaction was observed between region and treatment allocation. Conclusions: Although Asian patients had worse baseline profiles and outcomes, treatment effects did not differ by region, supporting the generalizability of early DOAC initiation in Asian AIS patients without region-specific timing modifications.

Indexed as

AnticoagulantsAtrial fibrillationInfarctionIntracranial hemorrhageIschemic strokeSecondary prevention

Identifiers

PMID42237624
PMCPMC13243848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.